Compare NVMI & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVMI | DVA |
|---|---|---|
| Founded | 1993 | 1994 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Misc Health and Biotechnology Services |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 14.9B |
| IPO Year | 2001 | 2003 |
| Metric | NVMI | DVA |
|---|---|---|
| Price | $381.32 | $175.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | ★ $431.88 | $156.75 |
| AVG Volume (30 Days) | 420.9K | ★ 561.0K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 6.86 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $20.94 | $3.85 |
| Revenue Next Year | $19.53 | $3.07 |
| P/E Ratio | $56.79 | ★ $25.46 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $266.43 | $101.00 |
| 52 Week High | $615.99 | $247.49 |
| Indicator | NVMI | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 54.37 | 38.56 |
| Support Level | $356.50 | $173.99 |
| Resistance Level | $387.71 | $202.63 |
| Average True Range (ATR) | 10.88 | 5.17 |
| MACD | 4.78 | -0.20 |
| Stochastic Oscillator | 89.15 | 2.68 |
Nova Ltd is a provider of metrology and process control solutions used in semiconductor manufacturing. The company provides high-performance metrology solutions across the semiconductor fabrication lifecycle and develops differentiated inline metrology solutions deployed by a broad range of customers, including integrated circuit manufacturers. Its portfolio combines high-precision hardware and software, enabling customers to improve device performance, enhance yields, and accelerate time to market. Its products include Dimensional Metrology, Materials Metrology, Chemical Metrology, and Software Solutions. The company operates in China, Taiwan, R.O.C., the United States and other regions, with maximum revenue coming from China.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.